Healthcare / Medical Instruments & SuppliesBSE
$480.60
+3.70 (+0.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $584.1M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$152.3B
P/E
115.5x
↑EV/EBITDA
26.3x
↑ROE
6.6%
↑Gross Margin
63.9%
↑Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+27.0%
FCF CAGR
-8.1%
FCF margin
2.8%
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.80B · net income $1.33B · FCF $584.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.80B | $20.80B | $17.11B | $13.28B | $10.16B |
| Net Income | $1.33B | $1.33B | $834.6M | $830.6M | $941.0M |
| EBITDA | $6.15B | $6.15B | $4.99B | $4.07B | $2.84B |
| EPS | — | — | 2.78 | 2.63 | 2.98 |
| Gross Margin | 63.9% | 63.9% | 62.9% | 45.1% | 45.1% |
| Operating Margin | 14.1% | 14.1% | 13.2% | 15.2% | 15.1% |
| Net Margin | 6.4% | 6.4% | 4.9% | 6.3% | 9.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.51 | 0.72 | 1.36 |
| Current Ratio | 1.24 | 1.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $584.1M | $584.1M | $362.3M | $1.14B | $753.0M |
| Returns | |||||
| ROE | 6.6% | 6.6% | 4.5% | 6.2% | 14.9% |
| Valuation | |||||
| P/E | 115.53 | 115.53 | 156.10 | — | — |
| EV/EBITDA | 26.33 | 26.33 | 27.80 | — | — |
| P/B | 7.52 | 7.52 | 6.98 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 21.6% | 21.6% | 28.9% | 30.6% | — |
| EPS Growth | — | — | 5.7% | -11.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.3%
Start / end P/E
n/dx → n/dx
EPS bridge
2.78 → n/d
Residual
+24.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.